DeepMed Research

Royal Marsden NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.royalmarsden.nhs.uk

Clinical Trials

Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.

Not Applicable

Conditions: Toxicity Due to Radiotherapy
Metastasis
Prostate Cancer
Circulating Tumour DNA

Interventions: Radiation: SBRT + ADT

First Posted Date: 2018-08-23

Last Posted Date: 2019-11-14

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 84

Registration Number: NCT03644303

Locations: 🇬🇧
Belfast Health & Social care Trust, Belfast, Northern Ireland, United Kingdom
🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Velindre Cancer Centre, Cardiff, Wales, United Kingdom

and more 4 locations

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Phase 2

Active, not recruiting

Conditions: Gastric Cancer
Lobular Breast Carcinoma
CDH1 Gene Mutation
Triple Negative Breast Cancer

Interventions: Drug: Crizotinib Oral Capsule [Xalkori]
Drug: Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic]

First Posted Date: 2018-08-08

Last Posted Date: 2023-12-22

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 58

Registration Number: NCT03620643

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust, London, United Kingdom

and more 2 locations

HRQoL in Advanced Soft Tissue Sarcoma Patients Treated With Chemotherapy.

Conditions: Quality of Life

Interventions: Other: Questionnaire

First Posted Date: 2018-08-08

Last Posted Date: 2018-08-13

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 132

Registration Number: NCT03621332

Locations: 🇬🇧
Royal Marsden Hospital, London, United Kingdom

Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

Phase 1

Conditions: Soft-tissue Sarcoma

Interventions: Drug: Compound 451238

First Posted Date: 2018-07-27

Last Posted Date: 2021-12-15

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 12

Registration Number: NCT03602833

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Simplification of Low Level Internal Dosimetry

Completed

Conditions: Exposure to Medical Diagnostic Radiation

Interventions: Other: 68-Ga Dotatate PET/CT dosimetry scans and measurements
Other: 18-F FDG PET/CT dosimetry scans and measurements
Other: Ga-68 PSMA PET/CT dosimetry scans and measurements
Other: 99mTc DMSA(III) Renal dosimetry scans and measurements
Other: 99mTc Pertechnetate Thyroid dosimetry scans and measurements
Other: 99mTc MAG3 Renal dosimetry scans and measurements
Other: 99mTc MDP/HDP Bone dosimetry scans and measurements

First Posted Date: 2018-07-09

Last Posted Date: 2023-06-27

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 12

Registration Number: NCT03580161

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Machine Learning in Myeloma Response

Not Applicable

Conditions: Myeloma

Interventions: Other: Machine Learning (ML)

First Posted Date: 2018-07-02

Last Posted Date: 2022-01-11

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 50

Registration Number: NCT03574454

Locations: 🇬🇧
Imperial College, London, London, United Kingdom
🇬🇧
Department of Radiology, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Institute of Cancer Research, London, London, United Kingdom

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

Phase 1

Completed

Conditions: Melanoma and Sarcoma

Interventions: Drug: Talimogene laherparepvec (T-VEC)

First Posted Date: 2018-06-13

Last Posted Date: 2021-08-18

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 15

Registration Number: NCT03555032

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Radiation Exposure Awareness From Patients Undergoing Nuclear Medicine Diagnostic Scans

Conditions: FDG PET/CT
Skeletal Scintigraphy

Interventions: Other: Self-administered questionnaire

First Posted Date: 2018-03-08

Last Posted Date: 2018-06-29

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 100

Registration Number: NCT03458585

Locations: 🇬🇧
The Royal Marsden Hospital NHS Trust Foundation, Sutton, Surrey, United Kingdom

PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients

Phase 1

Terminated

Conditions: Metastatic Non-small-cell lunG Cancer

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
Radiation: Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)
Radiation: Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose
Drug: Pembrolizumab

First Posted Date: 2018-02-19

Last Posted Date: 2022-09-09

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 2

Registration Number: NCT03436056

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Procedure: Radiotherapy planning using both CT and MRI scans

First Posted Date: 2018-01-23

Last Posted Date: 2020-08-17

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 1

Registration Number: NCT03405519

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy